Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

It is likely that Novartis will exercise the option. That is because Conatus and Galectin Therapeutics are the only biotech companies working on NASH Cirrhosis. novartis has covered NASH Fibrosis extensively, but has no NASH Cirrhosis drug in its pipeline. With CNAT and GALT being the only games in town it's down between those two. Although GALT has already failed an advanced NASH Fibrosis trial i doubt the NASH cirrhosis does any better but we shall see. Conatus is in good shape.